Overview of EBV antibody status and EBV-specific T-cells in SLE patients and healthy controls
| EBNA1 | EBV-EA/D | |||||
|---|---|---|---|---|---|---|
| IgG | IgA | IgM | IgG | IgA | IgM | |
| EBV antibody status | ||||||
| SLE patients (n=22), % | 86 | 14 | 32 | 73 | 64 | 27 |
| Healthy controls (n=22), % | 95 | 5 | 9 | 9 | 9 | 5 |
| EBNA1 | EBV-EA/D | |||||
| Total | CD8 | CD4 | Total | CD8 | CD4 | |
| EBV-specific (CD69) T-cell status | ||||||
| SLE patients (n=22), % | 41 | 32 | 27 | 23 | 18 | 14 |
| Healthy controls (n=22), % | 95 | 77 | 91 | 68 | 68 | 59 |
EBV, Epstein–Barr virus; EBNA1, EBV nuclear antigen 1; EBV-EA/D, EBV early antigen diffuse; SLE, systemic lupus erythematosus.